HLA-C

HLA class I histocompatibility antigen, C alpha chain · P10321 · HLA-C on Sugi Atlas →

0 patent compounds predicted against HLA-C, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to HLA-C by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) PHASE3COMPLETED
Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB PHASE3ACTIVE_NOT_RECRUITING
HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation PHASE3UNKNOWN
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System PHASE1/PHASE2COMPLETED
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Intra Bone Marrow Injection Of Unrelated Cord Blood Cells PHASE1/PHASE2UNKNOWN
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors PHASE2COMPLETED
Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies PHASE2COMPLETED
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity PHASE2RECRUITING
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations PHASE2RECRUITING
Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601) PHASE2COMPLETED
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma PHASE2ACTIVE_NOT_RECRUITING
Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized PHASE2NOT_YET_RECRUITING
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation PHASE1/PHASE2COMPLETED
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma PHASE1COMPLETED
Infusions of Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome PHASE1WITHDRAWN
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia PHASE1NOT_YET_RECRUITING
TCR-Redirected T Cells Therapy in Patient With HBV Related HCC PHASE1UNKNOWN
Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma. EARLY_PHASE1RECRUITING
Role of Human Leukocyte Antigen Matching in Liver Transplantation and Its Relation to Outcomes nanCOMPLETED
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia nanCOMPLETED
Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease nanRECRUITING
The Relationship Between HLA Tissue Compatibility and Biliary Complications in Patients With Liver Transplantation nanCOMPLETED
LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers nanRECRUITING
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults nanRECRUITING
High Resolution Donor Recipient HLA Matching Level in Unrelated HSCT nanCOMPLETED
HLA-DQ in Acute Kidney Transplantation Rejection nanCOMPLETED
HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan nanRECRUITING
Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes nanACTIVE_NOT_RECRUITING
In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients With Stabilized NMO nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a HLA-C binder may also engage these)

ProteinNameSimilarity
P30686 1.000 P30686 →
P30387 1.000 P30387 →
P13749 1.000 P13749 →
P13747 1.000 P13747 →
P30383 1.000 P30383 →
P30385 1.000 P30385 →
HLA-A HLA class I histocompatibility antigen, A alpha chain 1.000 landscape →
P06140 1.000 P06140 →
P30386 1.000 P30386 →
P13748 1.000 P13748 →
P16210 1.000 P16210 →
P01893 1.000 P01893 →
P14427 1.000 P14427 →
P13752 1.000 P13752 →
P16212 1.000 P16212 →
P30516 1.000 P30516 →
P30375 1.000 P30375 →
P30382 1.000 P30382 →
P18466 1.000 P18466 →
P30379 1.000 P30379 →
Q95IT3 1.000 Q95IT3 →
P01894 1.000 P01894 →
P30388 1.000 P30388 →
P13751 1.000 P13751 →
P14426 1.000 P14426 →
P30517 1.000 P30517 →
P16209 0.999 P16209 →
P01898 0.999 P01898 →
HLA-B HLA class I histocompatibility antigen, B alpha chain 0.999 landscape →
P33617 0.999 P33617 →